Exscientia Logo

Pipeline

Our pipeline demonstrates the ability of our AI-driven drug discovery platform to create precision engineered, patient-centric therapeutic candidates.

Programme

Target

Late Discovery

IND-enabling

Phase 1/2

Phase 3 / Approved*

Exscientia Rights

* Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes.